Predict your next investment

Venture Capital
inkefcapital.com

See what CB Insights has to offer

Investments

70

Portfolio Exits

17

Funds

1

About INKEF Capital

INKEF Capital provides long term capital and business advice to starting entrepreneurs in the Netherlands. From the very early stages of a high tech venture, INKEF Capital supports entrepreneurs building ideas into a successful business. Providing seed capital to turn a great idea into a company or providing growth capital to give a running start-up the next push, INKEF Capital is the partner for the long haul.

INKEF Capital Headquarter Location

Symphony Building Gustav Mahlerplein 3-115

Amsterdam, 1082 MS,

Netherlands

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest INKEF Capital News

Belgian biotech company Precirix secures €80M from Amsterdam-based INKEF Capital, others

Mar 17, 2022

Brussels-based Precirix , a platform developing radio-immunotherapeutic drugs for cancer patients, announced on Wednesday that it has raised €80M in its Series B round of funding. The round was led by new investors INKEF Capital, Jeito Capital, and Forbion as co-leads. With this, Simone Botti, Partner at INKEF Capital, Sabine Dandiguian, Managing Partner at Jeito and Jasper Bos, General Partner at Forbion Growth will join Precirix’s Board of Directors.

INKEF Capital Investments

70 Investments

INKEF Capital has made 70 investments. Their latest investment was in Precirix as part of their Series B on March 3, 2022.

CBI Logo

INKEF Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/16/2022

Series B

Precirix

$87.92M

Yes

7

3/15/2022

Series B

ChannelEngine

$50M

No

12

3/10/2022

Series A - II

Scenic Biotech

$31M

No

9

2/22/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/15/2022

Unattributed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/16/2022

3/15/2022

3/10/2022

2/22/2022

2/15/2022

Round

Series B

Series B

Series A - II

Series A

Unattributed VC

Company

Precirix

ChannelEngine

Scenic Biotech

Subscribe to see more

Subscribe to see more

Amount

$87.92M

$50M

$31M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

12

9

10

10

INKEF Capital Portfolio Exits

17 Portfolio Exits

INKEF Capital has 17 portfolio exits. Their latest portfolio exit was Cashforce on June 16, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/16/2022

Acquired

$99M

1

4/25/2022

Acquired

$99M

3

2/7/2022

Acquired

$99M

4

1/24/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/21/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2022

4/25/2022

2/7/2022

1/24/2022

10/21/2021

Exit

Acquired

Acquired

Acquired

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

3

4

10

10

INKEF Capital Fund History

1 Fund History

INKEF Capital has 1 fund, including Inkef Capital.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/24/2010

Inkef Capital

Early-Stage Venture Capital

Closed

$245.03M

1

Closing Date

6/24/2010

Fund

Inkef Capital

Fund Type

Early-Stage Venture Capital

Status

Closed

Amount

$245.03M

Sources

1

INKEF Capital Team

6 Team Members

INKEF Capital has 6 team members, including current Chief Executive Officer, Michael Stam.

Name

Work History

Title

Status

Michael Stam

Chief Executive Officer

Current

Roel Bulthuis

Managing Director

Current

Robert Galema

Managing Director

Current

Robert Jan Galema

Managing Director

Current

Dirk Kersten

Rivean Capital, and Gilde Healthcare Partners

Managing Director

Current

Name

Michael Stam

Roel Bulthuis

Robert Galema

Robert Jan Galema

Dirk Kersten

Work History

Rivean Capital, and Gilde Healthcare Partners

Title

Chief Executive Officer

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.